ProCE Banner Activity

My Experience With CAR T-Cell Therapy: Key Considerations

Case Challenge
Clinical Thought
Review my approach to CAR T-cell therapy—including considerations for patient candidacy and managing toxicities—illustrated with a patient case from my practice.

Released: October 17, 2019

Expiration: October 15, 2020

No longer available for credit.

Share

Faculty

Stephen J. Schuster

Stephen J. Schuster, MD

Robert and Margarita Louis-Dreyfus Professor of CLL and Lymphoma
Division of Hematology/Oncology
Department of Medicine
University of Pennsylvania
Director, Lymphoma Program and Lymphoma Translational Research
Abramson Cancer Center
Hospital of the University of Pennsylvania
Philadelphia, Pennsylvania

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an educational grant from

Celgene

Kite A GILEAD Company

Faculty Disclosure

Primary Author

Stephen J. Schuster, MD

Robert and Margarita Louis-Dreyfus Professor of CLL and Lymphoma
Division of Hematology/Oncology
Department of Medicine
University of Pennsylvania
Director, Lymphoma Program and Lymphoma Translational Research
Abramson Cancer Center
Hospital of the University of Pennsylvania
Philadelphia, Pennsylvania

Stephen J. Schuster, MD, has disclosed that he has received consulting fees from AbbVie, Aptitude Health, Celgene, Juno, Loxo Oncology, Nordic Nanovector, Novartis, and Tessa Therapeutics and funds for research support from AbbVie, Celgene, Genentech, Juno, Loxo Oncology, Merck, and Novartis.